Lower vs Higher Oxygenation Target and Days Alive Without Life Support in COVID-19
JAMA · 2024
DOI: 10.1001/jama.2024.2934 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2024. Verfasst von Frederik M Nielsen und 44 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesia and Intensive Care, Aalborg University Hospital, Aalborg, Denmark. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Supplemental oxygen is ubiquitously used in patients with COVID-19 and severe hypoxemia, but a lower dose may be beneficial.
Objective
To assess the effects of targeting a Pa o 2 of 60 mm Hg vs 90 mm Hg in patients with COVID-19 and severe hypoxemia in the intensive care unit (ICU). Design, Setting, and Participants Multicenter randomized clinical trial including 726 adults with COVID-19 receiving at least 10 L/min of oxygen or mechanical ventilation in 11 ICUs in Europe from August 2020 to March 2023. The trial was prematurely stopped prior to outcome assessment due to slow enrollment. End of 90-day follow-up was June 1, 2023.
Interventions
Patients were randomized 1:1 to a Pa o 2 of 60 mm Hg (lower oxygenation group; n = 365) or 90 mm Hg (higher oxygenation group; n = 361) for up to 90 days in the ICU. Main Outcomes and Measures The primary outcome was the number of days alive without life support (mechanical ventilation, circulatory support, or kidney replacement therapy) at 90 days. Secondary outcomes included mortality, proportion of patients with serious adverse events, and number of days alive and out of hospital, all at 90 days.
Results
Of 726 randomized patients, primary outcome data were available for 697 (351 in the lower oxygenation group and 346 in the higher oxygenation group). Median age was 66 years, and 495 patients (68%) were male. At 90 days, the median number of days alive without life support was 80.0 days (IQR, 9.0-89.0 days) in the lower oxygenation group and 72.0 days (IQR, 2.0-88.0 days) in the higher oxygenation group ( P = .009 by van Elteren test; supplemental bootstrapped adjusted mean difference, 5.8 days [95% CI, 0.2-11.5 days]; P = .04). Mortality at 90 days was 30.2% in the lower oxygenation group and 34.7% in the higher oxygenation group (risk ratio, 0.86 [98.6% CI, 0.66-1.13]; P = .18). There were no statistically significant differences in proportion of patients with serious adverse events or in number of days alive and out of hospital. Conclusion and Relevance In adult ICU patients with COVID-19 and severe hypoxemia, targeting a Pa o 2 of 60 mm Hg resulted in more days alive without life support in 90 days than targeting a Pa o 2 of 90 mm Hg. Trial Registration ClinicalTrials.gov Identifier: NCT04425031
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Anaesthesia and Intensive Care, Aalborg University Hospital, Aalborg, Denmark.
- Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
- Department of Intensive Care and Department of Clinical Research, Basel University Hospital, Basel, Switzerland.
- Department of Anaesthesia and Intensive Care, Division of Emergencies and Critical Care, Rikshospitalet Medical Centre, Oslo University Hospital, Oslo, Norway.
- Department of Anesthesia and Intensive Care, Landspitali, University Hospital of Reykjavik, Reykjavik, Iceland.
- Department of Intensive Care, Cardiff University Hospital of Wales, Cardiff, Wales.
Zitieren
APA
Nielsen, F. M., Klitgaard, T. L., Siegemund, M., Laake, J. H., Thormar, K. M., Cole, J. M., Aagaard, S. R., Bunzel, A. G., Vestergaard, S. R., Langhoff, P. K., Pedersen, C. H., Hejlesen, J. Ø., Abdelhamid, S., Dietz, A., Gebhard, C. E., Zellweger, N., Hollinger, A., Poulsen, L. M., Weihe, S., …, & HOT-COVID Trial Group (2024). Lower vs Higher Oxygenation Target and Days Alive Without Life Support in COVID-19. JAMA. https://doi.org/10.1001/jama.2024.2934
Vancouver
Nielsen FM, Klitgaard TL, Siegemund M, Laake JH, Thormar KM, Cole JM, et al. Lower vs Higher Oxygenation Target and Days Alive Without Life Support in COVID-19. JAMA. 2024. doi:10.1001/jama.2024.2934
BibTeX
@article{Nielsen2024,
author = {Nielsen, Frederik M and Klitgaard, Thomas L and Siegemund, Martin and Laake, Jon H and Thormar, Katrin M and Cole, Jade M and Aagaard, Søren R and Bunzel, Anne-Marie G and Vestergaard, Stine R and Langhoff, Peter K and Pedersen, Caroline H and Hejlesen, Josefine Ø and Abdelhamid, Salim and Dietz, Anna and Gebhard, Caroline E and Zellweger, Nuria and Hollinger, Alexa and Poulsen, Lone M and Weihe, Sarah and Andersen-Ranberg, Nina C and Pedersen, Ulf G and Mathiesen, Ole and Andreasen, Anne Sofie and Brix, Helene and Thomsen, Jonas J and Petersen, Christina H and Bestle, Morten H and Wichmann, Sine and Lund, Martin S and Mortensen, Karoline M and Brand, Björn A and Haase, Nicolai and Iversen, Susanne A and Marcussen, Klaus V and Brøchner, Anne C and Borup, Morten and Grøfte, Thorbjørn and Hildebrandt, Thomas and Kjær, Maj-Brit N and Engstrøm, Janus and Lange, Theis and Perner, Anders and Schjørring, Olav L and Rasmussen, Bodil S and HOT-COVID Trial Group, HOT-COVID Trial Group},
title = {Lower vs Higher Oxygenation Target and Days Alive Without Life Support in COVID-19},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2024.2934}
}
EUVIMED